ERBB2 and Hereditary breast cancer: The study provides preclinical evidence that supports opportunities and interest in using the newest generation inhibitors against HER2 and HER2-antibody drug conjugates to assess treatments for lobular breast cancer in the intraductal preclinical model in the future.